Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00772499 · ClinicalTrials.gov registry record · Phase 4
Vascular Improvement With Olmesartan Medoxomil Study
A Phase 4 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT00772499 is a Phase 4 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 100 participants.
The verdict
NCT00772499, a Phase 4 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to compare in patients with primary hypertension, the non-blood pressure lowering effects of one-year therapy with olmesartan medoxomil vs. those of atenolol on changes in the vascular structure and function.
Interventions
- DRUG olmesartan medoxomil + hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure
- DRUG atenolol+ hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2002-11 |
| Est. Completion | 2005-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00772499
The ClinicalTrials.gov registry entry for NCT00772499 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which olmesartan medoxomil + hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure is the first listed.
NCT00772499 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00772499 about?
NCT00772499 is a clinical study titled "Vascular Improvement With Olmesartan Medoxomil Study". The purpose of this study is to compare in patients with primary hypertension, the non-blood pressure lowering effects of one-year therapy with olmesartan medoxomil vs. those of atenolol on changes in the vascular structure and function.
What is the current status of trial NCT00772499?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2002-11. Estimated completion is 2005-07.
What interventions are being tested in trial NCT00772499?
The interventions under investigation include: olmesartan medoxomil + hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure (DRUG), atenolol+ hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure (DRUG).
Who is sponsoring clinical trial NCT00772499?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.